Cagrilintide is a long-acting analog of amylin, the fullness hormone the pancreas releases alongside insulin. It signals satiety, slows gastric emptying, and cuts food intake through a pathway that runs parallel to GLP-1 rather than duplicating it. That complementarity is why amylin plus incretin combinations, the CagriSema pairing with semaglutide being the headline example, outperform either agent alone.
- A long-acting amylin analog that signals satiety, slows gastric emptying, and reduces food intake.PubMed: cagrilintide
- Its mechanism is complementary to GLP-1 drugs, which is why amylin plus GLP-1 stacks outperform either one alone.PubMed: cagrilintide
- In GLP-1 class research, women lost more weight than men at matched exposure while reporting more GI effects.PubMed: GLP-1 sex differences
- In men, GLP-1 research showed testosterone, SHBG and gonadotropins rising as weight dropped, with sperm and erectile function improving and fertility preserved, unlike TRT.Jensterle 2020
- Reported adverse effects are GI (nausea, vomiting, constipation or diarrhea) plus injection-site reactions, and the GI effects scale with exposure.Peptide Guide, safety